Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

Publication

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

Journal Paper/Review - Jan 23, 2023

Núñez Nicolás Gonzalo, Berner Fiamma, Friebel Ekaterina, Unger Susanne, Wyss Nina

Citation

Núñez N, Berner F, Friebel E, Unger S, Wyss N. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med 2023; 4:113-129.e7.

Type

Journal Paper/Review (English)

Journal

Med 2023; 4

Publication Date

Jan 23, 2023

Issn Electronic

2666-6340

Pages

113-129.e7

Brief description/objective

Immune checkpoint inhibitors (ICIs) are among the most promising treatment options for melanoma and non-small cell lung cancer (NSCLC). While ICIs can induce effective anti-tumor responses, they may also drive serious immune-related adverse events (irAEs). Identifying biomarkers to predict which patients will suffer from irAEs would enable more accurate clinical risk-benefit analysis for ICI treatment and may also shed light on common or distinct mechanisms underpinning treatment success and irAEs.